SG11202106895UA - Heterodimeric proteins for modulating gamma delta t cells - Google Patents

Heterodimeric proteins for modulating gamma delta t cells

Info

Publication number
SG11202106895UA
SG11202106895UA SG11202106895UA SG11202106895UA SG11202106895UA SG 11202106895U A SG11202106895U A SG 11202106895UA SG 11202106895U A SG11202106895U A SG 11202106895UA SG 11202106895U A SG11202106895U A SG 11202106895UA SG 11202106895U A SG11202106895U A SG 11202106895UA
Authority
SG
Singapore
Prior art keywords
cells
gamma delta
heterodimeric proteins
modulating gamma
modulating
Prior art date
Application number
SG11202106895UA
Inventor
Taylor Schreiber
George Fromm
Silva Suresh De
Original Assignee
Shattuck Labs Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shattuck Labs Inc filed Critical Shattuck Labs Inc
Publication of SG11202106895UA publication Critical patent/SG11202106895UA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
SG11202106895UA 2019-01-07 2020-01-07 Heterodimeric proteins for modulating gamma delta t cells SG11202106895UA (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201962789344P 2019-01-07 2019-01-07
US201962876346P 2019-07-19 2019-07-19
US201962941176P 2019-11-27 2019-11-27
PCT/US2020/012589 WO2020146393A1 (en) 2019-01-07 2020-01-07 Heterodimeric proteins for modulating gamma delta t cells

Publications (1)

Publication Number Publication Date
SG11202106895UA true SG11202106895UA (en) 2021-07-29

Family

ID=71521410

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202106895UA SG11202106895UA (en) 2019-01-07 2020-01-07 Heterodimeric proteins for modulating gamma delta t cells

Country Status (12)

Country Link
US (2) US20220025000A1 (en)
EP (1) EP3902557A4 (en)
JP (1) JP2022516964A (en)
KR (1) KR20210113244A (en)
CN (1) CN113329759A (en)
AU (1) AU2020205965A1 (en)
BR (1) BR112021013193A2 (en)
CA (1) CA3125474A1 (en)
IL (1) IL284658A (en)
MX (1) MX2021008022A (en)
SG (1) SG11202106895UA (en)
WO (1) WO2020146393A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022197821A1 (en) * 2021-03-16 2022-09-22 Shattuck Labs, Inc. Gamma delta t-cell costimulation
WO2023154812A1 (en) * 2022-02-09 2023-08-17 Shattuck Labs, Inc. Multispecific heterodimeric proteins

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1499339A4 (en) 2002-04-12 2008-04-02 Univ Yale Anti-inflammatory and wound healing effects of lymphoid thymosin beta 4
AU2003238251B2 (en) 2002-06-17 2009-05-21 Wyeth Inhibition of T cell activation by butyrophilin 4 or B7-L1
EP1702622A1 (en) 2005-03-18 2006-09-20 CONARIS research institute AG Soluble BTNL2 protein useful to inhibit inflammatory disorders
WO2008154516A2 (en) 2007-06-11 2008-12-18 The Board Of Regents, The Universtity Ot Texas System Btnl2 fusion protein for t-cell activity modulation
GB0717101D0 (en) 2007-09-03 2007-10-10 Cambridge Entpr Ltd Tumour marker
AU2011237365B2 (en) 2010-04-09 2015-01-29 Amgen Inc. BTNL9 proteins, nucleic acids, and antibodies and uses thereof
CN105001330B (en) * 2010-04-23 2020-05-01 弗·哈夫曼-拉罗切有限公司 Production of heteromultimeric proteins
KR102049803B1 (en) * 2011-10-27 2019-11-29 젠맵 에이/에스 Production of heterodimeric proteins
US10131709B2 (en) 2011-12-28 2018-11-20 Immunoqure Ag Nucleic acid molecules encoding monoclonal antibodies specific for IL-22
US9957319B2 (en) 2011-12-28 2018-05-01 Immunoqure Ag Method of isolating human antibodies
AU2013292510A1 (en) 2012-07-19 2015-02-05 Amgen Inc. Human BTNL3 proteins, nucleic acids, and antibodies and uses thereof
EP2941438A1 (en) 2013-01-01 2015-11-11 Kahr Medical Ltd. Stable form of signal converting protein fusion proteins, and methods of use and preparation thereof
GB201300049D0 (en) 2013-01-03 2013-02-20 Transimmune Ag Method for obtaining immuno-stimulatory dendritic cells
GB201300052D0 (en) 2013-01-03 2013-02-20 Transimmune Ag Method for obtaining immuno-suppressive dendritic cells
WO2015001047A1 (en) 2013-07-03 2015-01-08 Immunoqure Ag Method of providing anti-human cytokine antibodies for pharmaceutical use
US10112995B2 (en) 2013-07-03 2018-10-30 Immunoqure Ag Human anti-IFN-α antibodies
KR102231685B1 (en) 2013-07-03 2021-03-26 이뮤노큐어 아게 Human anti-il-32 antibodies
EP3074040A4 (en) 2013-11-29 2017-06-28 CSL Limited Method of treating cancer
EA039086B1 (en) 2014-04-10 2021-12-01 Лава Терапьютикс Н.В. Immunoglobulins binding human v9v2 t cell receptors
GB201413665D0 (en) 2014-07-03 2014-09-17 Transimmune Ag And Yale University Method for obtaining globally activated monocytes
US20180296636A1 (en) * 2014-11-25 2018-10-18 Albert Einstein College Of Medicine, Inc. Btnl9 and ermap as novel inhibitors of the immune system for immunotherapies
BR112017018368B1 (en) 2015-04-22 2022-08-02 Curevac Ag COMPOSITION CONTAINING RNA FOR USE IN THE TREATMENT OR PROPHYLAXIS OF TUMOR AND/OR CANCER DISEASES, AND USE OF AN RNA FOR THE PREPARATION OF THE COMPOSITION
US20180147257A1 (en) 2015-05-22 2018-05-31 The Board Of Trustees Of The Leland Stanford Junior University Btn3a ectodomain proteins and methods of use
UA126549C2 (en) * 2015-10-01 2022-11-02 Хіт Байолоджикс, Інк. Compositions and methods for adjoining type i and type ii extracellular domains as heterologous chimeric proteins
AU2016344779B2 (en) 2015-10-30 2023-01-05 Cancer Research Technology Limited Expansion of non-haematopoietic tissue-resident gamma delta T cells and uses of these cells
CA3006769A1 (en) 2015-12-02 2017-06-08 Stcube & Co., Inc. Antibodies and molecules that immunospecifically bind to btn1a1 and the therapeutic uses thereof
GB201521389D0 (en) * 2015-12-03 2016-01-20 Ucb Biopharma Sprl Method
CN115850521A (en) * 2016-02-05 2023-03-28 奥里尼斯生物科学私人有限公司 Targeted therapeutic agents and uses thereof
KR20230031373A (en) 2016-03-29 2023-03-07 주식회사 에스티큐브앤컴퍼니 Methods for selecting antibodies that specifically bind glycosylated immune checkpoint proteins
WO2018082590A1 (en) * 2016-11-02 2018-05-11 北京蛋白质组研究中心 Tumor immunotherapy target and application thereof
US20200188482A1 (en) 2017-04-28 2020-06-18 The Brigham And Women`S Hospital, Inc. Targeting gamma-delta t cells in obesity and cachexia
US20200148768A1 (en) 2017-05-31 2020-05-14 Stcube & Co., Inc. Antibodies and molecules that immunospecifically bind to btn1a1 and the therapeutic uses thereof
CN111051346A (en) 2017-05-31 2020-04-21 斯特库伯株式会社 Methods of treating cancer using antibodies and molecules that immunospecifically bind to BTN1a1
WO2018226671A1 (en) 2017-06-06 2018-12-13 Stcube & Co., Inc. Methods of treating cancer using antibodies and molecules that bind to btn1a1 or btn1a1-ligands
WO2018229163A1 (en) 2017-06-14 2018-12-20 King's College London Methods of activating v delta 2 negative gamma delta t cells
US20200297871A1 (en) 2017-09-15 2020-09-24 King's College London Compositions and methods for enhancing gamma delta t cells in the gut
KR20200133323A (en) 2017-09-21 2020-11-27 임체크 테라퓨틱스 에스에이에스 Antibodies with specificity for BTN2 and uses thereof
US11098093B2 (en) * 2019-01-07 2021-08-24 Shattuck Labs, Inc. Heterodimeric proteins for modulating gamma delta T cells

Also Published As

Publication number Publication date
CN113329759A (en) 2021-08-31
EP3902557A1 (en) 2021-11-03
WO2020146393A1 (en) 2020-07-16
KR20210113244A (en) 2021-09-15
MX2021008022A (en) 2021-08-05
JP2022516964A (en) 2022-03-03
US20220025000A1 (en) 2022-01-27
US20230020258A1 (en) 2023-01-19
AU2020205965A1 (en) 2021-07-01
BR112021013193A2 (en) 2021-09-28
US11643447B2 (en) 2023-05-09
CA3125474A1 (en) 2020-07-16
IL284658A (en) 2021-08-31
EP3902557A4 (en) 2023-06-07

Similar Documents

Publication Publication Date Title
IL281954A (en) Heterodimeric fc-fused proteins
IL285543A (en) Modified natural killer (nk) cells for immunotherapy
EP3952890A4 (en) Methods and compositions for programming t cell differentiation and enhancing t cell proliferation
SG11202103192RA (en) Il-12 heterodimeric fc-fusion proteins
EP3873923A4 (en) Multivalent regulatory t cell modulators
ZA202100125B (en) Novel fusion protein specific for cd137 and pd-l1
IL290595A (en) Compositions and methods for modulating splicing and protein expression
EP3949998A4 (en) Cell activator
IL284658A (en) Heterodimeric proteins for modulating gamma delta t cells
IL291618A (en) Heterodimeric proteins
IL280553A (en) Cell culture strategies for modulating protein glycosylation
IL286681A (en) Compounds and methods for modulating ube3a-ats
GB201904971D0 (en) Cell
GB201819540D0 (en) T cell modification
EP4058565A4 (en) Methods for reprogramming cells
GB201906202D0 (en) Cell
EP4045043A4 (en) Compounds and methods for modulating immune-related proteins
EP4085129A4 (en) Containers and methods for cell transduction
EP4048783C0 (en) Modified cell
GB202005879D0 (en) Heterodimeric proteins
EP4059572A4 (en) Cell reprogramming method
EP3938495A4 (en) Recombinant eril-15 nk cells
EP3864138A4 (en) Compositions and methods for modifying regulatory t cells
EP3799113A4 (en) Ceramic package for filling liquid-component containing electrolyte
GB2587795B (en) An electro-optic modulator